- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01783639
Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting (WISE)
June 29, 2017 updated by: Gardia Medical
The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with embolic protection studies
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patient registry procedures include:
- Clinical Events Committee (CEC); responsibility for validating all reported primary safety outcomes
- Data Safety Monitoring Board (DSMB); to review and evaluate safety data including serious adverse events
- 100% data monitoring; to compare data entered into the registry
- Source data verification; to assess the accuracy, completeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms).
- Standard Operating Procedures; to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis and reporting for adverse events.
- Sample size assessment to specify the number of participants and follow up duration.
- Data Management Plan; to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results
- Statistical analysis plan; describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dendermonde, Belgium, 9200
- AZ Sint Blasius Hospital, Department of Vascular Surgery
-
-
-
-
-
Bad-Krozingen, Germany, 79189
- Universitaets Herzzentrum
-
Berlin, Germany, 13347
- Ihre-Radiologen.de
-
Dortmund, Germany, 44137
- Klinikum Dortmund GmbH
-
Frankfurt, Germany, 60389
- Cardiovascular Center Frankfurt
-
Hamburg, Germany, 22527
- Hamburg University Cardiovascular Center
-
Leipzig, Germany, 04289
- Herzzentrum and Park-Krankenhaus
-
Munich, Germany, 87137
- Städtisches Klinikum München GmbH Klinikum Neuperlach
-
-
-
-
-
Cotignola, Italy, 48010
- Villa Maria Cecilia Hospital
-
Mirano, Italy, 30035
- Mirano Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age
- Anticipated patient life expectancy of at least 1 year
- Patient or authorized representative, signed a written Informed Consent form
- Patient is willing to comply with the protocol requirements
- Candidate for catheter-based therapy of a single stenosis located in the internal carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single FDA-approved stent with a carotid use indication
- Reference vessel diameter for intended filter location between 3.5mm and 6.0mm
- An adequate "landing zone" of at least 30mm
- Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50% for symptomatic patients OR ≥ 80% for asymptomatic patients
- At least one high surgical risk criteria, either anatomical or co-morbid risk factors, as listed below:
Category I - Anatomical high risk factors
- Recurrent stenosis after endarterectomy
- Previous radical neck surgery or radiation therapy to the neck
- High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle
- Spinal immobility of the neck
- Tracheostomy or tracheal stoma
- Any laryngeal nerve palsy and bilateral carotid artery stenosis
Category II - Co-morbid risk factors
- Contralateral carotid occlusion
- Unstable angina (Canadian Cardiovascular Society class III/IV)
- Congestive Heart Failure (New York Heart Association functional class III/IV) and/or known severe left ventricular dysfunction LVEF<30%
- Requires coronary artery bypass surgery, cardiac valve surgery, major vascular surgery, or abdominal aortic aneurysm repair 31-60 days post carotid stent procedure
- Recent MI (>72 hr and <4 weeks)
- Severe pulmonary disease with FEV1 of <30%
- CAD in ≥2 unrevascularized vessels with stenosis ≥70%
- Age ≥75 years
- Uncontrolled diabetes - Female patient with no child bearing potential or has negative pregnancy test within the previous 7 days and agrees to remain on birth control throughout the study
Exclusion Criteria:
- Total occlusion or near-occlusion of the target vessel
- Severe lesion calcification
- Presence of an alternate source of emboli
- Presence of a filling defect, or angiographically visible thrombus, at target site
- A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion more severe than the target lesion
- Evolving, acute or recent stroke within the last 30 days
- Major stroke with a residual neurological deficit that would confound neurologic assessment
- Vertebrobasilar insufficiency symptoms only
- Major operation 30 days before or after the index procedure
- Ipsilateral intracranial stenosis that requires treatment
- Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in contralateral carotid within 30 days of the index procedure
- History of intracranial hemorrhage within 12 months
- Any condition that precludes proper angiographic assessment or prevents femoral arterial access
- Uncontrolled hypertension
- Contraindication to heparin and bivalirudin, aspirin, thienopyridines
- Known sensitivity to radiographic contrast media which cannot be controlled with pre-medication
- History or current indication of bleeding diathesis or coagulopathy
- Chronic renal insufficiency
- Carotid artery dissection or aortic arch anatomical anomalies
- Dementia or a neurological illness
- Patient is enrolled in another drug or device study protocol that has not reached its primary endpoint
- Severe pulmonary hypertension
- Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study participation inappropriate or confound neurologic assessment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Device: WIRION™ Embolic Protection System Interventions: Carotid Artery Stent |
Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Rate of Peri-procedural (Within 30 Days of Procedure) Death, Stroke, and Myocardial Infarction.
Time Frame: Within 30 Days of procedure
|
Each participant will be followed for 30 days of procedure during which the number of major cardiac and cerebral adverse events (Stroke, Death and Myocardial Infraction) will be counted to evaluate the device safety.
|
Within 30 Days of procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Rate of Device Success
Time Frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Defined as a successful delivery, deployment and retrieval of WIRION™ without any complications
|
Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
The Rate of Clinical Success
Time Frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Defined as freedom from procedure related serious adverse events
|
Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
The Rate of Access Site Complications
Time Frame: Within 30 Days of procedure
|
Within 30 Days of procedure
|
|
Neurological Events Occurring Within 30 Days Post Procedure,Including Strokes and Transient Ischemic Attacks
Time Frame: Within 30 Days of procedure
|
Within 30 Days of procedure
|
|
Angiographic Success
Time Frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Successful completion of the protected stent procedure without angiographic complications
|
Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Procedural Success
Time Frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Defined as both device and angiographic success
|
Participants will be followed for the duration of the procedure, an expected average of 35 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dierk Scheinert, MD, Herzzentrum Leipzig GmbH and Park-Krankenhaus Leipzig
- Principal Investigator: Horst Sievert, MD, Cardio Vascular Center Frankfurt
- Principal Investigator: Stefan Rohde, MD, Radiologische Klinik, Klinikum Dortmund GmbH
- Principal Investigator: Joachim Schofer, MD, Universitäres Herz- und Gefäßzentrum Hamburg
- Principal Investigator: Harald Mudra, MD, Städtisches Klinikum München GmbH
- Principal Investigator: Marc Bosiers, MD, AZ St-Blasius, Dendermonde
- Principal Investigator: Thomas Zeller, MD, Universitaets Herzzentrum, Bad-Krozingen
- Principal Investigator: Alberto Cremonesi, MD, Villa Maria Cecilia, Contignola
- Principal Investigator: Bernhard Reimers, MD, Mirano Hospital
- Principal Investigator: Henrik Schröder, MD, Ihre-Radiologen.de
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
January 13, 2013
First Submitted That Met QC Criteria
February 1, 2013
First Posted (Estimate)
February 5, 2013
Study Record Updates
Last Update Posted (Actual)
August 7, 2017
Last Update Submitted That Met QC Criteria
June 29, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WIRION™ Pivotal Study (WISE)
- WIRION Study Europe (WISE) (Other Identifier: Gardia Medical Ltd.)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Carotid Artery Stent
-
University of Maryland, BaltimoreMayo Clinic; National Institute of Neurological Disorders and Stroke (NINDS); Centers for Medicare and Medicaid Services and other collaboratorsRecruiting
-
W.L.Gore & AssociatesCompleted
-
Rutgers, The State University of New JerseyUniversity of Alabama at Birmingham; National Institute of Neurological Disorders...CompletedMyocardial Infarction | Stroke | Atherosclerosis | Carotid Stenosis | Cerebral InfarctionUnited States, Canada
-
Dallas VA Medical CenterCompleted
-
Providence Health & ServicesCompleted
-
Carmel Medical CenterCompletedCarotid StenosisIsrael
-
Peking Union Medical College HospitalRecruiting
-
John Paul II Hospital, KrakowInspireMDRecruitingCarotid Artery DiseasesPoland
-
Microvention-Terumo, Inc.Active, not recruitingCarotid Artery StenosisUnited States
-
Jagiellonian UniversityTerminatedStroke, Ischemic | Carotid Atherosclerosis | Carotid Artery Stenosis